Is Kenvue Stock Outperforming the S&P 500?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Source: NASDAQ.COM
Company Overview: Kenvue Inc. (KVUE), a consumer health company with a market cap of $43.6 billion, operates in three segments and offers well-known brands like Tylenol and Listerine. Despite recent struggles, KVUE has outperformed the S&P 500 over the past year.
Stock Performance and Outlook: Following a disappointing Q4 earnings report, KVUE's stock declined but analysts maintain a "Moderate Buy" rating with a price target suggesting slight upside, while the company anticipates modest growth in organic sales and adjusted EPS.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 18.86 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.750
Low
17.00
Averages
18.86
High
23.00
Current: 17.750
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
